Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea

Last updated: March 14, 2019
Sponsor: Yonsei University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Non-ulcer Dyspepsia (Nud)

Ulcers

Gastrointestinal Diseases And Disorders

Treatment

N/A

Clinical Study ID

NCT02184910
4-2013-0722
  • Ages > 19
  • Female

Study Summary

It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects of age, sex, and Helicobacter pylori status on pepsinogen (PG) level for atrophic gastritis and whether gastric atrophy based on the PG test would be improved after H. pylori eradication.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. over 19 years

  2. the patients who have gastrointestinal discomfort or get esophagogastroduodenoscopy (EGD) for health check up

  3. the patients who got the procedure, endoscopic submucosal resection (ESD) for earlygastric cancer

Exclusion

Exclusion Criteria:

  1. gastrectomy history

  2. advanced gastric cancer (impossible to get the gastrectomy)

  3. Helicobacter eradication history

  4. the patients who have chronic disease

  5. cancer patients except gastric cancer within 6 months

  6. who cannot perform this study according to research's decision

  7. who have bleeding tendency (ex. taking antiplatelet agent, low platelet count orabnormal coagulation time)

Study Design

Total Participants: 108
Study Start date:
December 01, 2013
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • Severance hospital

    Seoul, 120-752
    Korea, Republic of

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.